23 Mar 2017 14:57
Realm Therapeutics plc
("Realm Therapeutics" or the "Company")
Annual Report and Accounts Available
23 March 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, confirms that, further to the announcement of its Final Results today, an electronic copy of the Annual Report and Accounts for the year ended 31 December 2016 is now available on the Company's website, www.realmtx.com.
Enquiries:
Realm Therapeutics plc | +44 (0) 20 3727 1000 |
Alex Martin, Chief Executive Officer Marella Thorell, Chief Financial Officer and Chief Operating Officer |
|
|
|
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway / Mo Noonan |
|
|
|
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
Aubrey Powell / Lauren Kettle |
|
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children. The Company has initiated drug development programmes, based on its proprietary hypochlorous acid technology at high concentrations. The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.
RLM.L (RLM)